BioSpace News Archive

Bio NC

Humacyte Announces Date of Annual Shareholder Meeting

Humacyte, Inc. announced that its 2022 annual meeting of shareholders will be held virtually on Thursday, June 9, 2022, at 7:30 AM eastern time.

April 4, 2022
·
1 min read
Drug Development

Positive New Data from Phase 1/2 Trial of AT-01 Presented at 2022 American College of Cardiology Annual Scientific Session

Attralus, Inc. announced encouraging new clinical data from the University of Tennessee Graduate School of Medicine from its Phase 1/2 trial of iodine evuzamitide, the company’s pan-amyloid binding peptide in development as a radiotracer for the diagnosis of systemic amyloidosis.

April 4, 2022
·
6 min read
Biotech Bay

Aligos Therapeutics Selects Drug Candidate ALG-097558, a Potent Ritonavir-Free Oral Protease Inhibitor for the Treatment and Prevention of COVID-19

Aligos Therapeutics, Inc. today announced that it has selected ALG-097558, a broad spectrum coronavirus protease inhibitor, as its drug candidate to move forward into development.

April 4, 2022
·
7 min read
FDA

FDA approves Nobelpharma’s HYFTOR™ (sirolimus topical gel) 0.2%

Nobelpharma America, LLC today announced that the U.S. Food and Drug Administration (FDA) has approved HYFTOR™ (sirolimus topical gel) 0.2% as the first topical treatment indicated for facial angiofibroma associated with TSC in adults and children six (6) years of age or older1.

April 4, 2022
·
7 min read
FDA

TSC Alliance® Welcomes FDA Approval of Topical Treatment for Facial Angiofibromas

Today the TSC Alliance® applauds the U.S. Food and Drug Administration’s (FDA’s) approval of HYFTOR™, which is the first FDA-approved topical treatment for facial angiofibromas in adults and children six years of age or older who have tuberous sclerosis complex (TSC).

April 4, 2022
·
2 min read
Biotech Beach

Equillium Announces Oral Presentation at the Italian Society of Experimental Hematology

Equillium, Inc. announced an oral presentation at the 2022 National Congress of the Italian Society of Experimental Hematology in Rome, Italy.

April 4, 2022
·
7 min read
BioForest

Alpine Immune Sciences Publishes Key Preclinical Rationale for Davoceticept (ALPN-202), a First-in-Class CD28 Costimulator and Dual Checkpoint Inhibitor, in Nature Communications

Alpine Immune Sciences Publishes Key Preclinical Rationale for Davoceticept (ALPN-202), a First-in-Class CD28 Costimulator and Dual Checkpoint Inhibitor, in Nature Communications.

April 4, 2022
·
5 min read
Drug Development

PhaseBio Announces Positive Results from Phase 2b Trial for Bentracimab

PhaseBio Pharmaceuticals, Inc. today announced the complete results from its Phase 2b clinical trial of bentracimab that were presented on April 2nd during a Late Breaking Featured Clinical Research Presentation at the American College of Cardiology’s 71st Annual Scientific Session (ACC.22).

April 4, 2022
·
9 min read
Business

Alzamend Neuro Appoints Dr. Terri Hunter to Its Scientific Advisory Board

Alzamend Neuro, Inc. today announced the appointment of Dr. Terri Hunter, Ph.D., a Technology Transfer Specialist, to its Scientific Advisory Board.

April 4, 2022
·
7 min read
Genetown

PerkinElmer Introduces First Ready-to-use HTRF® and AlphaLISA® Assay Kits for CHO HCP Impurities Detection and Quantification

PerkinElmer, Inc. today announced two ready-to-use HTRF® and AlphaLISA® no-wash assay kits designed to quickly and easily detect and quantify CHO HCP impurities during biopharmaceutical manufacturing.

April 4, 2022
·
2 min read